Less Is More: A Hypofractionated Approach

This 66-year-old gentleman1 would benefit from neoadjuvant immunotherapy (IO), namely cemiplimab, which is an anti –programmed cell death protein 1 monoclonal antibody. A phase 2 multicenter study found administration of cemiplimab every 2 weeks resulted in an objective response rate in 44% of patients (13% complete response and 31% partial response) with a durable response in 63%.2 A more recent analysis foun d durable long-term disease-free survival among those who had a pathologic response.3
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research